There was substantial variability in aspects of diet examined and methods of dietary assessment used.
Secondly, there are large differences in microbial distributions between the two diets examined, regardless of the 16S database used (16S_Merge, Fig. 1B and C and 16S_Ref, Supplementary Fig. S1).
Additionally, we aimed to examine effects of specific depression characteristics on diet by examining if diet quality varies between patients with distinct subtypes of depression, and if depression severity is associated with diet quality.
Many studies reported food added ad libitum, but among the subset of studies that reported diet values, 25% examined diet gradients.
Whereas a larger elevation in triglycerides was observed in trials limited to weight-maintenance diets, the LFHC diet did not significantly elevate triglycerides compared with the HFLC diet when only trials with weight-loss diets were examined (i.e., diets for weight loss) (P = 0.48).
Since vessel changes were consistently found in 100% of the 4-week old Gcdh−/−mice after initiation of protein diet, we examined semi-thin sections from each of 12-hour intervals after diet exposure to capture the evolution of this process.
We fed mice from middle age (14-months) to old age (30-months) either a control diet, a low dose of resveratrol (4.9 mg kg−1 day−1), or a calorie restricted (CR) diet and examined genome-wide transcriptional profiles.
Otis et al. placed Sprague Dawley rats on an ethanol diet consisting of 36% of total calories, perfused the lungs after 6 weeks of special diet, and examined protein from whole lung homogenate for α1 subunit.
The influence of yerba mate extract (YME) and two concentrated fractions of methylxanthines polyphenols (MXPL) and saponins (SFL) from yerba mate on the lipid metabolism of Wistar rats fed with a high-fat diet were examined.
Herein we used female C57BL/6J mouse models for type 1 diabetes (streptozotocin [STZ] treatment) and type 2 diabetes (high-fat diet) to examine the ability of 4b,5,9b,10-tetrahydroindeno[1,2-b]indole (THII) to intervene in the progression of diabetes.
